Disease-free interval length correlates to prognosis of patients who underwent metastasectomy for esophageal lung metastases

Background: Pulmonary metastasectomy is a standard method for treatment of selected Pulmonary metastases cases. Nevertheless, because prognosis for patients with lung metastases from esophageal cancer who have undergone Pulmonary metastasectomy is poor, candidates for this method of treatment are rare. Therefore, the efficacy Of surgical treatment for Pulmonary metastatic lesions From esophageal cancer has not been thoroughly examined. Methods: Between March 1984 and May 2006 57 patients underwent resection Of pulmonary metastases from primary esophageal cancer. These cases were registered in the database developed by the Metastatic Lung Tumor Study Group of Japan and were retrospectively reviewed from the registry. After excluding eight cases because of missing information, we reviewed the remaining 49 cases and examined the prognostic factors for pulmonary metastasectomy for metastases from esophageal cancer. Results: There were no perioperative deaths. After Pulmonary metastasectomy, disease recurred in 16 (33%) of the 49 patients. The overall 5-year survival was 29.6%. Median survival time was 18 months. The survival of patients with it disease-free interval (DFI) less than 12 months was significantly lower than patients with a DFI greater than 12 months. Through multivariate analysis, we identified DFI as a clinical factor significantly related to overall Survival (p 0.04). Conclusions: We identified that patients with a DFI less than 12 months who underwent I)pulmonary metastasectomy for metastases from esophageal cancer had a worse prognosis. pulmonary metastasectomy for esophageal cancer Should be considered for selected patients with a DFI >= 12 months.